Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes
Copyright © 2023 Massachusetts Medical Society..
BACKGROUND: Hybrid closed-loop insulin therapy has shown promise for management of type 1 diabetes during pregnancy; however, its efficacy is unclear.
METHODS: In this multicenter, controlled trial, we randomly assigned pregnant women with type 1 diabetes and a glycated hemoglobin level of at least 6.5% at nine sites in the United Kingdom to receive standard insulin therapy or hybrid closed-loop therapy, with both groups using continuous glucose monitoring. The primary outcome was the percentage of time in the pregnancy-specific target glucose range (63 to 140 mg per deciliter [3.5 to 7.8 mmol per liter]) as measured by continuous glucose monitoring from 16 weeks' gestation until delivery. Analyses were performed according to the intention-to-treat principle. Key secondary outcomes were the percentage of time spent in a hyperglycemic state (glucose level >140 mg per deciliter), overnight time in the target range, the glycated hemoglobin level, and safety events.
RESULTS: A total of 124 participants with a mean (±SD) age of 31.1±5.3 years and a mean baseline glycated hemoglobin level of 7.7±1.2% underwent randomization. The mean percentage of time that the maternal glucose level was in the target range was 68.2±10.5% in the closed-loop group and 55.6±12.5% in the standard-care group (mean adjusted difference, 10.5 percentage points; 95% confidence interval [CI], 7.0 to 14.0; P<0.001). Results for the secondary outcomes were consistent with those of the primary outcome; participants in the closed-loop group spent less time in a hyperglycemic state than those in the standard-care group (difference, -10.2 percentage points; 95% CI, -13.8 to -6.6); had more overnight time in the target range (difference, 12.3 percentage points; 95% CI, 8.3 to 16.2), and had lower glycated hemoglobin levels (difference, -0.31 percentage points; 95% CI, -0.50 to -0.12). Little time was spent in a hypoglycemic state. No unanticipated safety problems associated with the use of closed-loop therapy during pregnancy occurred (6 instances of severe hypoglycemia, vs. 5 in the standard-care group; 1 instance of diabetic ketoacidosis in each group; and 12 device-related adverse events in the closed-loop group, 7 related to closed-loop therapy).
CONCLUSIONS: Hybrid closed-loop therapy significantly improved maternal glycemic control during pregnancy complicated by type 1 diabetes. (Funded by the Efficacy and Mechanism Evaluation Program; AiDAPT ISRCTN Registry number, ISRCTN56898625.).
| Errataetall: |
CommentIn: N Engl J Med. 2024 Jan 11;390(2):183. - PMID 38197822 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:389 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 389(2023), 17 vom: 26. Okt., Seite 1566-1578 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Tara T M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Blood Glucose |
|---|
| Anmerkungen: |
Date Completed 30.10.2023 Date Revised 06.03.2024 published: Print-Electronic ISRCTN: ISRCTN56898625 CommentIn: N Engl J Med. 2024 Jan 11;390(2):183. - PMID 38197822 Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMoa2303911 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362899622 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362899622 | ||
| 003 | DE-627 | ||
| 005 | 20240306232444.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa2303911 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM362899622 | ||
| 035 | |a (NLM)37796241 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Tara T M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.10.2023 | ||
| 500 | |a Date Revised 06.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ISRCTN: ISRCTN56898625 | ||
| 500 | |a CommentIn: N Engl J Med. 2024 Jan 11;390(2):183. - PMID 38197822 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Massachusetts Medical Society. | ||
| 520 | |a BACKGROUND: Hybrid closed-loop insulin therapy has shown promise for management of type 1 diabetes during pregnancy; however, its efficacy is unclear | ||
| 520 | |a METHODS: In this multicenter, controlled trial, we randomly assigned pregnant women with type 1 diabetes and a glycated hemoglobin level of at least 6.5% at nine sites in the United Kingdom to receive standard insulin therapy or hybrid closed-loop therapy, with both groups using continuous glucose monitoring. The primary outcome was the percentage of time in the pregnancy-specific target glucose range (63 to 140 mg per deciliter [3.5 to 7.8 mmol per liter]) as measured by continuous glucose monitoring from 16 weeks' gestation until delivery. Analyses were performed according to the intention-to-treat principle. Key secondary outcomes were the percentage of time spent in a hyperglycemic state (glucose level >140 mg per deciliter), overnight time in the target range, the glycated hemoglobin level, and safety events | ||
| 520 | |a RESULTS: A total of 124 participants with a mean (±SD) age of 31.1±5.3 years and a mean baseline glycated hemoglobin level of 7.7±1.2% underwent randomization. The mean percentage of time that the maternal glucose level was in the target range was 68.2±10.5% in the closed-loop group and 55.6±12.5% in the standard-care group (mean adjusted difference, 10.5 percentage points; 95% confidence interval [CI], 7.0 to 14.0; P<0.001). Results for the secondary outcomes were consistent with those of the primary outcome; participants in the closed-loop group spent less time in a hyperglycemic state than those in the standard-care group (difference, -10.2 percentage points; 95% CI, -13.8 to -6.6); had more overnight time in the target range (difference, 12.3 percentage points; 95% CI, 8.3 to 16.2), and had lower glycated hemoglobin levels (difference, -0.31 percentage points; 95% CI, -0.50 to -0.12). Little time was spent in a hypoglycemic state. No unanticipated safety problems associated with the use of closed-loop therapy during pregnancy occurred (6 instances of severe hypoglycemia, vs. 5 in the standard-care group; 1 instance of diabetic ketoacidosis in each group; and 12 device-related adverse events in the closed-loop group, 7 related to closed-loop therapy) | ||
| 520 | |a CONCLUSIONS: Hybrid closed-loop therapy significantly improved maternal glycemic control during pregnancy complicated by type 1 diabetes. (Funded by the Efficacy and Mechanism Evaluation Program; AiDAPT ISRCTN Registry number, ISRCTN56898625.) | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Glycated Hemoglobin |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Insulin |2 NLM | |
| 700 | 1 | |a Collett, Corinne |e verfasserin |4 aut | |
| 700 | 1 | |a Bergford, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Hartnell, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Scott, Eleanor M |e verfasserin |4 aut | |
| 700 | 1 | |a Lindsay, Robert S |e verfasserin |4 aut | |
| 700 | 1 | |a Hunt, Katharine F |e verfasserin |4 aut | |
| 700 | 1 | |a McCance, David R |e verfasserin |4 aut | |
| 700 | 1 | |a Barnard-Kelly, Katharine |e verfasserin |4 aut | |
| 700 | 1 | |a Rankin, David |e verfasserin |4 aut | |
| 700 | 1 | |a Lawton, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Reynolds, Rebecca M |e verfasserin |4 aut | |
| 700 | 1 | |a Flanagan, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Hammond, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Shepstone, Lee |e verfasserin |4 aut | |
| 700 | 1 | |a Wilinska, Malgorzata E |e verfasserin |4 aut | |
| 700 | 1 | |a Sibayan, Judy |e verfasserin |4 aut | |
| 700 | 1 | |a Kollman, Craig |e verfasserin |4 aut | |
| 700 | 1 | |a Beck, Roy |e verfasserin |4 aut | |
| 700 | 1 | |a Hovorka, Roman |e verfasserin |4 aut | |
| 700 | 1 | |a Murphy, Helen R |e verfasserin |4 aut | |
| 700 | 0 | |a AiDAPT Collaborative Group |e verfasserin |4 aut | |
| 700 | 1 | |a Hunt, Katharine |e investigator |4 oth | |
| 700 | 1 | |a Rogers, Helen |e investigator |4 oth | |
| 700 | 1 | |a Morris, Damian |e investigator |4 oth | |
| 700 | 1 | |a Fowler, Duncan |e investigator |4 oth | |
| 700 | 1 | |a Rosier, Josephine |e investigator |4 oth | |
| 700 | 1 | |a Banu, Zeenat |e investigator |4 oth | |
| 700 | 1 | |a Barker, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Rayman, Gerry |e investigator |4 oth | |
| 700 | 1 | |a Gurnell, Eleanor |e investigator |4 oth | |
| 700 | 1 | |a Byrne, Caroline |e investigator |4 oth | |
| 700 | 1 | |a Lake, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Davenport, Katy |e investigator |4 oth | |
| 700 | 1 | |a Grisoni, Jeannie |e investigator |4 oth | |
| 700 | 1 | |a Savine, Shannon |e investigator |4 oth | |
| 700 | 1 | |a Murphy, Helen R |e investigator |4 oth | |
| 700 | 1 | |a Lee, Tara T M |e investigator |4 oth | |
| 700 | 1 | |a Wallace, Tara |e investigator |4 oth | |
| 700 | 1 | |a McKelvey, Alastair |e investigator |4 oth | |
| 700 | 1 | |a Willer, Nina |e investigator |4 oth | |
| 700 | 1 | |a Turner, Elizabeth |e investigator |4 oth | |
| 700 | 1 | |a Collett, Corinne |e investigator |4 oth | |
| 700 | 1 | |a Man, Mei-See |e investigator |4 oth | |
| 700 | 1 | |a Flanagan, Emma |e investigator |4 oth | |
| 700 | 1 | |a Hammond, Matt |e investigator |4 oth | |
| 700 | 1 | |a Shepstone, Lee |e investigator |4 oth | |
| 700 | 1 | |a Brackenridge, Anna |e investigator |4 oth | |
| 700 | 1 | |a White, Sara |e investigator |4 oth | |
| 700 | 1 | |a Reid, Anna |e investigator |4 oth | |
| 700 | 1 | |a Okolo, Olanike |e investigator |4 oth | |
| 700 | 1 | |a Scott, Eleanor M |e investigator |4 oth | |
| 700 | 1 | |a Endersby, Del |e investigator |4 oth | |
| 700 | 1 | |a Dover, Anna |e investigator |4 oth | |
| 700 | 1 | |a Dougherty, Frances |e investigator |4 oth | |
| 700 | 1 | |a Johnston, Susan |e investigator |4 oth | |
| 700 | 1 | |a Reynolds, Rebecca M |e investigator |4 oth | |
| 700 | 1 | |a Lindsay, Robert |e investigator |4 oth | |
| 700 | 1 | |a Carty, David |e investigator |4 oth | |
| 700 | 1 | |a Mackin, Sharon |e investigator |4 oth | |
| 700 | 1 | |a Crawford, Isobel |e investigator |4 oth | |
| 700 | 1 | |a Buchan, Ross |e investigator |4 oth | |
| 700 | 1 | |a McCance, David |e investigator |4 oth | |
| 700 | 1 | |a Jones, Louisa |e investigator |4 oth | |
| 700 | 1 | |a Quinn, Joanne |e investigator |4 oth | |
| 700 | 1 | |a Cains, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Ayman, Goher |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 389(2023), 17 vom: 26. Okt., Seite 1566-1578 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:389 |g year:2023 |g number:17 |g day:26 |g month:10 |g pages:1566-1578 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa2303911 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 389 |j 2023 |e 17 |b 26 |c 10 |h 1566-1578 | ||